Aspen Pharmacare Australia has
advised of pending shortages of
all strengths of Permax (pergolyde
mesylate), with all current stock
held at its warehouse and in those
of wholesalers set to expire at the
end of this month.
The company said that expected
stock will not arrive, “as pergolide
is no longer readily available” but
it’s believed the ingredients will be
available later in the year.
However “we estimate it is
unlikely we will receive new stock
for the remainder of 2013,” Aspen
said, and during this period Permax
will be out of stock.
“There can be no emergency
supply due to dating issues,” the
company warned, with pharmacists
advised to tell their customers
to see their neurologist or other
health professional for alternative
treatment during this time.The above article was sent to subscribers in Pharmacy Daily's issue from 07 Aug 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Aug 13
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.